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Background: Non-invasive biomarkers of disease progression in mice with cancer are lacking making it challenging to implement
appropriate humane end points. We investigated whether body temperature, food and water consumption could be used to
predict tumour burden.
Methods: Thirty-six male, wild-type C57Bl/6 mice were implanted with subcutaneous RFID temperature sensors and inoculated
with Em-myc tumours that infiltrate lymphoid tissue.
Results: Decrease in body temperature over the course of the study positively predicted post-mortem lymph node tumour burden
(R2¼ 0.68, F(1,22)¼ 44.8, Po0.001). At experimental and humane end points, all mice that had a mean decrease in body
temperature of 0.7 1C or greater had lymph nodes heavier than 0.5 g (100% sensitivity), whereas a mean decrease in body
temperatureo0.7 1C always predicted lymph nodes lighter than 0.5 g (100% specificity). The mean decrease in food consumption
in each cage also predicted mean post-mortem lymph node tumour burden at 3 weeks (R2¼ 0.89, F(1,3)¼ 23.2, P¼ 0.017).
Conclusion: Temperature, food and water consumption were useful biomarkers of disease progression in mice with lymphoma
and could potentially be used more widely to monitor mice with other forms of cancer.
Animals continue to be used in cancer research as in vivo studies to
help elucidate mechanisms involved in the development/pathology
of cancers and are used to improve diagnostic methods and
treatment. A recent working party report concluded that studies
involving animals remain essential in cancer research but that it is
necessary to integrate the 3Rs (Replacement, Reduction and
Refinement) into this work as the appropriate use of animals is a
prerequisite to good science (Workman et al, 2010). The 3Rs
proposed by William Russell and Rex Burch in 1959 refer to the
replacement of animals used in research with non-sentient
alternatives, the reduction of the number of animals used in research
and the refinement of experimental and husbandry procedures to
minimise pain and distress (Russell and Burch, 1959).
The application of appropriate and objective humane end points
is essential when refining in vivo cancer research to minimise pain
and/or distress. Humane end points refer to ‘criteria that allow early
termination of experiments before animals experience significant
harm while still meeting the experimental objectives’ (NC3Rs, 2013).
One of the main obstacles to implementing humane end points is a
general lack of biomarkers that can be used as specific indicators of
disease progression (Franco et al, 2012), and this has been identified
as a particular concern in in vivo cancer research (Workman et al,
2010). Although sometimes tumour burden and disease progression
can be directly measured using callipers (e.g., subcutaneous
tumours) in many other cancer studies (e.g., thoracic, peritoneal
and lymphoreticular tumours), it cannot.
Imaging is frequently advocated as a method of tracking disease
progression in animals with cancer but repeated anaesthesia is
typically required, which may affect experimental outcomes and
have a welfare cost (Workman et al, 2010; Wong et al, 2013).
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Furthermore, imaging is financially costly, requires specialist skills
and equipment, and may not be carried out at a sufficient
frequency to detect critical points in disease progression. The use of
specific clinical signs as biomarkers has the advantage that they can
be obtained quickly and non-invasively. Weight loss is the most
frequently used clinical biomarker in disease studies, but reliance
on changes in body weight as a single indicator of disease
progression is problematic (Franco et al, 2012) particularly in
cancer research due to the weight of the tumours.
The aim of this study was therefore to identify biomarkers of
disease progression in mice with lymphoma. Rather than use
animals specifically for this study, enhanced monitoring of wild-
type mice implanted with Em-myc tumours that were involved in
an ongoing programme of work was carried out. Transgenic Em-
myc mice are widely used to study haematological malignancies
and are known to develop aggressive lymphoma (Harris et al,
1988). This strain is frequently crossed with other genetically
altered mice (e.g. with altered anti-apoptotic factors, Bcl-xl, Mcl-1)
to investigate the effects of different genes in vivo (Campbell et al,
2010; Kelly et al, 2011) and to test the efficacy of novel therapeutic
agents (Ferrao et al, 2012; Wall et al, 2013). In order to minimise
the heterogeneity and spontaneity of the tumours, primary tumour
cells are frequently obtained from the lymphoid organs of Em-myc
animals, grown ex vivo and implanted into multiple syngeneic
recipients. Mice implanted with Em-myc tumours typically develop
enlarged lymph nodes, spleens and thymus by 2–4 weeks post
implantation. However, there is often considerable variation in
disease progression depending on the primary tumour implanted
making it challenging to apply appropriate humane end points.
We hypothesised that body temperature might predict tumour
burden in mice implanted with Em-myc tumours. Temperature has
been used as a surrogate marker of imminent death in many fields
of in vivo research (Ray et al, 2010), and in cancer studies
persistent hypothermia has been identified as a severe clinical sign
necessitating immediate intervention (Workman et al, 2010).
Thermoregulation in mice is known to be energetically expensive
(Gaskill et al, 2013a), but there is a lack of detailed information on
how body temperature changes in mice developing cancer. A
secondary hypothesis was that directly measuring food and water
would provide an earlier predictor of disease onset at the cage level
compared with mean body weight.
MATERIALS AND METHODS
All procedures were carried out under project and personal
licences approved by the Secretary of State for the Home Office,
under the United Kingdom’s 1986 Animal (Scientific Procedures)
Act and approved by Newcastle University’s Animal Welfare and
Ethical Review Body. Thirty-six wild-type male C57BL/6 mice
obtained from Charles River Laboratories (Ramsgate, Kent, UK)
were studied. Animals were free from all major pathogens and drug
and test naive. Mice were housed in groups of 6 per cage in
individually ventilated cages (IVCs) (580 cm3, Maxiseal 580,
Arrowmight, Hereford, UK) with 20 air changes per hour. Aspen
woodchips (Tapvei, Datesand, Manchester, UK) and nesting
material (1 nestlet/3 mice (FDA Nestlets, Datesand, Manchester,
UK)) were used as bedding. Tap water and commercial pelleted
diet (R&M no.3, SDS limited, Whitham, UK) were available ad
libitum. The room was maintained at 23 1C±1 1C on a light cycle
(12 h/12 h, lights on at 0700 hours).
Transponder implantation was carried out 3 days before tumour
implantation by briefly anaesthetising mice with isoflurane then
subcutaneously injecting a transponder (2.2 14mm; 0.12 g; IPTT-
300, PLEXX BV, ELST, The Netherlands) into each animal. An
automated reader system (Vertical Smart Probe (VSP-7005)/DAS-
8001 Data Acquisition System/DAS-7001 wireless interface (PLEXX
BV, ELST, The Netherlands)) was used to read temperatures.
Temperatures were taken 5–7 days/week between 0800 and 1100
hours by sequentially taking cages off the IVC rack, removing cage
lids then placing readers directly adjacent to the cage (Figure 1) for
B5min. Readings were obtained (animal identification/time/
temperature) each time a mouse was within reading range
(5–8 cm) of the reader. Values greater than 40 1C or less than
33 1C and values that changed more than 3 1C within any 30 s period
were considered as outliers and excluded. Daily temperature for each
animal was the first valid temperature recorded. The food and water
consumption of each cage was also measured daily by weighing the
food hopper/water bottle and subtracting the measured weight of
food/water from the amount measured the previous day. Mice were
weighed following temperature readings.
Mice were randomly allocated to cage and tumour groups.
Animals were 8 weeks old with a mean body weight of 22.7 g
(s.e.m.¼ 0.25 g) when they were implanted with Em-myc tumour
cells. Cells had been collected from spontaneous lymphoid
tumours of Em-myc transgenic animals, frozen and cryogenically
stored as previously described (Mason et al, 2008). Tumour cells
were then re-implanted into other animals by intravenous
injections via the lateral tail vein of 1 106 viable cells in a
phosphate-buffered saline vehicle. Three primary tumours were
used and each was injected into 12 mice (1 primary tumour/2
cages). Clinical signs were recorded daily for each individual
mouse, using clinical observation sheets (Hawkins, 2002). Mice
were killed at pre-determined experimental end points 2, 3, 4 and 5
weeks post administration (3 mice killed/primary tumour at each
experimental end point) unless pre-defined severity limits were
approached or met. Mice were killed earlier than their planned
experimental end point if 2 experienced researchers (JEH, CAR)
considered disease severity to be moderate based on clinical
Figure 1. Position of RFID transponder reader next to homecage.
(A) Mice not exhibiting clinical signs of lymphoma (primary tumour 1,
experimental day 20). (B) Mice with clinical signs of lymphoma 1 day
before humane killing (primary tumour 3, experimental day 20).
Tracking disease progression in mice with lymphoma BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2013.818 929
impression or if they exhibited any of the clinical signs listed by
Workman et al (2010) as necessitating immediate intervention.
Mice were killed by an overdose of isoflurane, and organs were
subsequently collected and weighed. As lymphoma causes an
enlargement of lymphoid organs, tumour burden was measured as
the gross weight of the pooled lymph nodes (cervical, brachial,
inguinal and mesenteric), thymus and spleen.
All statistical analyses were conducted using IBM SPSS 19
software (IBM SPSS Inc, Armonk, NY, USA). The experimental
unit for all analyses was mouse with the exception of food/water
consumption where the cage was the experimental unit (individual
food and water consumption could not be measured in standard
individually ventilated cages). Because of the variation in baseline
values, changes in parameters over the course of the study were
studied (e.g., change from baseline values in body temperature,
body weight and food/water consumption). Change in body
temperature over the course of the study was calculated for each
mouse as the difference between mean temperature over the 3 days
before killing and the 3 days following tumour implantation.
Proportional weight loss for each individual was calculated as the
difference between final and maximum body weight compared
with maximum body weight (e.g., a mouse with a peak body weight
of 30 g over the course of the study who weighed 28 g at the end
point would be considered to have a proportional weight loss of
6.7%). The comparison was made with maximum body weight
(rather than baseline body weight) as growing mice were studied.
Simple linear regression was used to test whether clinical signs
(e.g., change in body temperature, proportional weight loss) predicted
tumour burden/weight in the lymphoid organs (pooled lymph nodes,
thymus and spleen) of each mouse. Fisher’s exact test was used to test
for association between clinical parameters (change in temperature
and weight loss) and tumour burden/ weight of pooled lymph nodes.
Differences in post-mortem organ weight were evaluated using a
multivariate general linear model with time point and tumour as
between-subject factors and pooled lymph node, thymus and spleen
weights as within-subject factors. One sample t-tests with a
Bonferonni correction were used to test for an overall change in
food/water consumption. Simple linear regression was also used to
test whether mean decrease in food and water consumption in each
cage predicted mean tumour burden/weight of the lymphoid organs
of the animals in the cage at 3 weeks. Proportional decrease in food/
water consumption was calculated as change in mean consumption
from experimental week 3 to 1 compared with mean consumption at
experimental week 1 (e.g., a cage of mice that consumed an average
of 3 g per day over experimental week 1 and 2 g per day over
experimental week 3 would have a decrease in food consumption of
33%.). Significance for all statistical tests was established at Po0.05,
data are presented as mean (±s.e.m.).
RESULTS
One mouse implanted with tumour 2 was killed on experimental
day 0 following an unsuccessful intravenous injection. Clinical
signs observed when humane end points were implemented
included ruffled coat, enlarged cervical lymph nodes and dull
demeanour (Figure 1B). With the exception of enlarged lymph
nodes, none of the mice exhibited clinical signs listed by Workman
et al (2010) as necessitating immediate intervention. On the basis
of clinical impression, primary tumour 1 was the least aggressive;
none of the mice implanted with tumour 1 were killed earlier than
pre-determined experimental end points. Six mice from each of
experimental groups implanted with primary tumours 2 and 3
were killed earlier than pre-determined experimental end points of
4 and 5 weeks (mice killed days 21–23 and classified as being killed
at the 3 week time point).
Six of the RFID transponders failed over the first 7 experimental
days (three from tumour group 1, two from tumour group 2, one
from tumour group 3). Data from the mice affected by the faulty
transponders are included in food/water consumption and body-
weight analysis but not body temperature analysis (Table 1). Less
than 1% of temperature readings were classed as outliers and
excluded based on pre-determined criteria.
Mean change in body temperature over the course of the study
predicted tumour burden in the lymph nodes (R2¼ 0.68,
F(1,22)¼ 44.8, Po0.001), thymus (R2¼ 0.51, F(1,22)¼ 21.6,
Po0.001) and spleen (R2¼ 0.31, F(1,22)¼ 9.5, P¼ 0.006) at
post-mortem (Figure 2A–C). Proportional change in body weight
also predicted tumour burden in the lymph nodes (R2¼ 0.31,
F(1,22)¼ 9.2, P¼ 0.006) (Figure 2D) but not the thymus or the
spleen (Figure 2E and F).
The data were examined post-hoc to determine whether any
clinical criteria reliably predicted disease progression. At experi-
mental and humane end points, a criterion of a mean decrease in
body temperature of 0.7 1C or greater would have always detected
mice with lymph nodes heavier than or equal to 0.5 g (100%
sensitivity) (Table 2). Similarly a criterion of a mean decrease in
body temperature o0.7 1C would have always detected lymph
nodes lighter than 0.5 grams (100% specificity) (Table 2). In
contrast, although a weight loss criterion of 5% or greater would
have 100% specificity for detecting lymph nodes heavier than 0.5 g,
sensitivity would decrease to 60% and 40% of mice with lymph
nodes heavier than 0.5 g would not have been detected (Table 2).
Associations between the temperature criterion of  0.7 1C and the
weight loss criterion of 5% with thymus and spleen tumour burden
are summarised in Table 2.
Post-mortem findings confirmed that tumour 1 was the least
aggressive primary tumour and there was an overall effect of both
time (F(3,21)¼ 3.1, P¼ 0.047) and primary tumour (F(6,44)¼ 4.3,
P¼ 0.002) on organ weight (lymph nodes, thymus and spleen)
(Figure 3A–C). In the two cages of mice implanted with primary
tumour 1, mean body weight of the animals increased over the 21
experimental days, and there was little daily variation in food or
water consumption (Figure 3D). In contrast, in cages with mice
implanted with primary tumours 2 and 3, mean body weight fell
over the last 4–5 experimental days, and both food and water
consumption began to decline from experimental day 12
(Figure 3E and F). The only clinical observation recorded over
the first 12 days of the study was fighting. Clinical signs of sickness
Table 1. Sample size at each endpoint
Time Food/water consumption Body weight Body temperature Organ weight
2 weeks Tumours 1–3: n¼2 Tumour 1: n¼ 12
Tumour 2: n¼ 11
Tumour 3: n¼ 12
Tumour 1: n¼ 9
Tumour 2: n¼ 9
Tumour 3: n¼ 11
Tumours 1–3: n¼3
3 weeks Tumours 1–3: n¼2 Tumour 1: n¼ 9
Tumour 2: n¼ 8
Tumour 3: n¼ 9
Tumour 1: n¼ 6
Tumour 2: n¼ 6
Tumour 3: n¼ 8
Tumour 1: n¼3
Tumour 2: n¼8
Tumour 3: n¼9
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for mice implanted with tumours 2 and 3 were noted from
experimental day 12 and are summarised in Table 3. Some of the
clinical signs summarised in Table 3 were also noted in mice
implanted with tumour 1 from experimental day 17. An increase in
burrowing behaviour was noted from experimental day 12 where
mice were observed to move around in their homecages with their
noses emerged in dirty bedding (Figure 4).
Over the first 2 weeks of the study, mean body temperature in
mice implanted with all 3 primary tumours was within 0.5 1C of
36 1C (Figure 3G–I). The mean body temperature of mice
implanted with primary tumours 2 and 3 decreased between
experimental weeks 2 and 3 (Figure 3H and I).
Between experimental weeks 1 and 3, there was an overall
decrease in both food consumption (t(4)¼ 9.6, P¼ 0.007) and
water consumption (t(4)¼ 6.9, P¼ 0.0024). At the cage level,
proportional decrease in food consumption (week 3 compared with
week 1) predicted mean tumour burden in the lymph nodes
(R2¼ 0.89, F(1,3)¼ 23.2, P¼ 0.017) and spleen (R2¼ 0.90,
F(1,3)¼ 27.1, P¼ 0.014) but not in the thymus (Figure 5A–C).
The proportional decrease in water consumption predicted tumour
burden in the thymus (R2¼ 0.83, F(1,3)¼ 14.7, P¼ 0.31) but not
in the lymph nodes or spleen (Figure 5D–F).
DISCUSSION
In this study, enhanced clinical monitoring of mice implanted with
Em-myc tumours elucidated stages of disease progression. The
criterion of a mean decrease in body temperature of 0.7 1C was a
sensitive and specific indicator of tumour burden in lymphoid
organs. As pain and distress are more likely to occur with greater
tumour burdens in mice with cancer (Workman et al, 2010),
humanely killing animals when tumour burden is as required for
experimental outcomes is likely to refine in vivo cancer studies.
Humanely killing animals at a uniform stage in disease
progression can also minimise variation in post-mortem findings
and reduce the overall number of animals required in in vivo
cancer research.
Our work provides further evidence to support how reliance on
weight loss as a biomarker of disease progression for mice with
lymphoma may be problematic (Paster et al, 2009). Mean body
weight did not begin to decrease until disease progression was
relatively advanced and several animals with large tumours did not
lose weight during the study.
In contrast to body weight, changes in body temperature did
predict tumour burden in the lymphoid organs. One potential
disadvantage of temperature as a biomarker of disease progression
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Figure 2. Relationships between clinical biomarkers and tumour burden. Circles indicate 2 week endpoint, squares indicate 3 week endpoint.
Tumour 1 in yellow, tumour 2 in red and tumour 3 in black. (A–C) Scatter plots to show relationships between change in body temperature and
total weight of lymph nodes (cervical, brachial, inguinal, mesenteric), thymus and spleen. (D–F) Scatter plots to show relationships between change
in body weight and total post-mortem weight of lymphoid organs.
Table 2. Contingency table of clinical parameters and post-mortem
organ weights
Mean change in body
temperature X0.7 1C
Change from maximum
body weight X5%
Negative
(%)
Positive
(%)
Negative
(%)
Positive
(%)
Pooled lymph node weight (g)
o0.5g 13 (100%) 0 (0%) 13 (100%) 0 (0%)
X0.5g 0 (0%) 10 (100%) 4 (40%) 6 (60%)
P value o0.0001 0.0021
Thymus weight (g)
o0.2g 12 (92%) 1 (8%) 12 (92%) 1 (8%)
X0.2g 1 (10%) 9 (90%) 5 (50%) 5 (50%)
P-value 0.0001 NS
Spleen weight (g)
o0.3g 7 (88%) 1 (12%) 7 (88%) 1 (12%)
X0.3g 6 (40%) 9 (60%) 10 (67%) 5 (33%)
P-value NS NS
Abbreviation: NS¼not significant.
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is the natural variability in body temperature, influenced by a large
number of factors, including time of day, activity and activation of
the sympathetic nervous system (Van Bogaert et al, 2006). When
studying temperature in relation to disease progression it is
therefore important to be consistent in the way that temperature is
taken. To minimise the effects of time of day and stress induced
hyperthermia (Bouwknecht and Olivier, 2007), in this study mean
changes in the temperature of socially housed animals in their
homecage were studied and temperature was always measured in
the morning typically at the transition from sleeping to waking
when the lid was removed from each cage. Because of non-
pathological variation in temperature and occasional outlier
readings, the decision to implement a humane end point should
not be made solely based on a single reading but mean changes in
body temperature should be considered alongside other clinical
markers (e.g., changes in appearance of the animals’ coat,
demeanour, social interactions and posture). Clinical criteria that
have been identified as relevant in mice with other types of
lymphoma include body condition scores, general appearance
(particularly coat condition) and natural behaviours (e.g., decrease
in activity) (Paster et al, 2009) as well as decreased rearing,
exploration and grooming (van Loo et al, 1997). In rodents with
other cancers, relevant clinical indicators include hunching and
vocalisation in mice with pancreatic cancer (Lindsay et al, 2005)
and hunching, vocalisation and starey coats in rats with bladder
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Figure 3. Tumour burden and changes in clinical biomarkers with disease progression. (A–C) Organ weights at post-mortem classified by primary
tumour implanted (mean±s.e.m.). Two week endpoints in blue, 3 week endpoints in green. (D–F) Changes in food/water consumption and
body weight following tumour implantation on experimental day 0. Data plotted as mean±s.e.m. (mean body weight calculated from individual
values; mean food/water consumption calculated from cage values). Body weight is in green, water consumption is in red and food consumption
is in black. (G–I) Change in temperature following tumour implantation plotted as 3-day moving averages (meanþ / s.e.m.).
Table 3. Summary table of clinical observations noted from experimental
day 12 to end points
Type of clinical
observation Terms used to describe clinical observations
Change in coat Dull, starey, ruffled, decreased grooming
Demeanour Dull
Social interactions Socially isolated, huddled
Posture Hunched, ears tilted back from baseline position
Body systems Pale, increased respiratory rate, sunken eyes
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cancer (Roughan et al, 2004). The further identification and
dissemination of relevant clinical signs and biomarkers in mice
with cancer should be encouraged (Kilkenny et al, 2010;
Workman et al, 2010).
The criteria of 0.7 1C decrease in body temperature and 5%
weight loss were determined post-hoc and further studies are
required to assess the predictive validity of these values. Similarly
further work is needed to determine the efficacy of other
non-invasive methods of measuring body temperature including
thermography cameras (Edgar et al, 2013; Gaskill et al, 2013a) and
non-contact infrared thermometers (Warn et al, 2003) for
monitoring mice with cancer.
Even if temperature is not monitored and used as a biomarker
of tumour growth in mice with Em-myc tumours, researchers
should be aware that, as lymphoma develops, mice may be less able
to thermoregulate. Recent studies have demonstrated that cold
stress can have a negative impact on the welfare of healthy
laboratory mice (Gaskill et al, 2011) as well as being a source of
significant experimental variability in mice with cancer (Kokolus
et al, 2013). Mice with Em-myc tumours should therefore be housed
with sufficient species-appropriate, naturalistic nesting material to
allow the animals to carry out behavioural thermoregulation (Hess
et al, 2008; Gaskill et al, 2012, 2013b). Similarly, more considera-
tion/investigation should be given to the most appropriate housing
temperature for in vivo cancer studies.
At the cage level, food and water consumption was early
indicator of disease onset as mean food/water consumption started
to fall several days earlier than body weight or temperature. Food
and water consumption has also been shown to decrease in socially
housed mice with other cancers such as subcutaneous prostate
cancer xenografts (Jacobsen et al, 2013). Measuring food/water
consumption by cage requires no specialised skills or equipment
and can be useful when animals are housed by the experimental
group and when disease progression is similar between animals.
Although it is not possible to use food/water consumption as the
basis for determining individual end points in mice housed socially
in individually ventilated cages, by quickly detecting the onset of
clinical signs refinements such as warmth or soaked diet can be
introduced to cages when most needed. When mice with
lymphoma are individually housed food and water consumption
also decreases with tumour growth (van Loo et al, 1997) and could
therefore be used to refine individual end points.
Provided that body temperature is taken and interpreted
carefully, this study indicates that it can be a useful biomarker of
Figure 4. Mouse exhibiting burrowing behaviour, moving forwards in
the cage with his nose immersed in dirty bedding. Picture taken on
experimental day 15.
2.0 1.0 0.6
0.4
0.2
0.0
0 20 40 60
Decrease in food consumption (%)
80 100
0 20 40 60
Decrease in water consumption (%)
80 100
0.8
0.6
0.4
0.2
0.0
y= 0.017x + 0.075
y= 0.0072x + 0.06
y= 0.006x + 0.19
1.5
1.0
0.5P
o
o
le
d 
LN
 (g
)
Th
ym
u
s 
(g)
1.0
0.8
0.6
0.4
0.2
0.0
Th
ym
u
s 
(g)
Sp
le
en
 (g
)
0.6
0.4
0.2
0.0
Sp
le
en
 (g
)
0.0
2.0
1.5
1.0
0.5P
o
o
le
d 
LN
 (g
)
0.0
0 20 40 60
Decrease in food consumption (%)
80 100
0 20 40 60
Decrease in water consumption (%)
80 100 0 20 40 60
Decrease in water consumption (%)
80 100
0 20 40 60
Decrease in food consumption (%)
80 100
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mesenteric), thymus and spleen. (D–F) Scatter plots to show relationships between decrease in water consumption and total post-mortem weight
of lymphoid organs.
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disease progression in mice with lymphoma and could potentially
be used more widely as a biomarker for mice with other cancers.
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